Fiona Chandra

Fiona Chandra specializes in the clinical development of telomerase inhibitors for hematologic malignancies, particularly myelofibrosis and myelodysplastic syndromes. She has led translational studies connecting telomere biology to clinical outcomes in patients treated with imetelstat. Her research integrates biomarker analyses of telomere length with treatment response in bone marrow failure syndromes. She has contributed to defining optimal patient populations for telomerase-targeting therapies.